Boston Scientific Co. (NYSE:BSX) Shares Acquired by Brookstone Capital Management

Brookstone Capital Management raised its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 23.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 105,860 shares of the medical equipment provider’s stock after purchasing an additional 20,307 shares during the period. Brookstone Capital Management’s holdings in Boston Scientific were worth $9,455,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the business. BOKF NA grew its holdings in shares of Boston Scientific by 14.0% during the second quarter. BOKF NA now owns 3,065 shares of the medical equipment provider’s stock valued at $236,000 after buying an additional 377 shares during the last quarter. Parallel Advisors LLC grew its holdings in shares of Boston Scientific by 15.3% during the second quarter. Parallel Advisors LLC now owns 11,790 shares of the medical equipment provider’s stock valued at $908,000 after buying an additional 1,562 shares during the last quarter. Thoroughbred Financial Services LLC purchased a new stake in shares of Boston Scientific during the second quarter valued at $203,000. J.W. Cole Advisors Inc. grew its holdings in shares of Boston Scientific by 9.2% during the second quarter. J.W. Cole Advisors Inc. now owns 3,989 shares of the medical equipment provider’s stock valued at $307,000 after buying an additional 336 shares during the last quarter. Finally, WINTON GROUP Ltd purchased a new stake in shares of Boston Scientific during the second quarter valued at $484,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Boston Scientific

In other news, Director Edward J. Ludwig sold 4,877 shares of the stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total value of $446,879.51. Following the completion of the sale, the director now owns 39,398 shares of the company’s stock, valued at $3,610,038.74. This represents a 11.02 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Arthur C. Butcher sold 14,010 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the completion of the sale, the executive vice president now directly owns 978 shares of the company’s stock, valued at approximately $87,306.06. This trade represents a 93.47 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 29,989 shares of company stock worth $2,702,261. Insiders own 0.50% of the company’s stock.

Boston Scientific Stock Down 0.1 %

BSX opened at $94.78 on Tuesday. Boston Scientific Co. has a twelve month low of $59.61 and a twelve month high of $97.13. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The company has a 50-day moving average price of $90.16 and a 200 day moving average price of $84.02. The company has a market cap of $139.69 billion, a PE ratio of 78.33, a price-to-earnings-growth ratio of 2.67 and a beta of 0.80.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. The company had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. Boston Scientific’s quarterly revenue was up 19.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.50 EPS. Sell-side analysts expect that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on BSX. Wells Fargo & Company boosted their price objective on shares of Boston Scientific from $98.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Canaccord Genuity Group upped their price target on shares of Boston Scientific from $98.00 to $101.00 and gave the company a “buy” rating in a report on Monday, December 9th. Truist Financial upped their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. StockNews.com lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Monday, November 4th. Finally, Evercore ISI upped their price target on shares of Boston Scientific from $82.00 to $90.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Three investment analysts have rated the stock with a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $97.26.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.